Cargando…

Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study

PURPOSE: Obesity and insulin resistance have been associated with poor prognosis in breast cancer (BC). The present prospective study aimed to investigate the impact of metabolic syndrome (MetS) and its components on early BC (eBC) patients’ outcome. METHODS: MetS was defined by the presence of 3 to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buono, Giuseppe, Crispo, Anna, Giuliano, Mario, De Angelis, Carmine, Schettini, Francesco, Forestieri, Valeria, Lauria, Rossella, De Laurentiis, Michelino, De Placido, Pietro, Rea, Carmen Giusy, Pacilio, Carmen, Esposito, Emanuela, Grimaldi, Maria, Nocerino, Flavia, Porciello, Giuseppe, Giudice, Aldo, Amore, Alfonso, Minopoli, Anita, Botti, Gerardo, De Placido, Sabino, Trivedi, Meghana V., Arpino, Grazia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297840/ https://www.ncbi.nlm.nih.gov/pubmed/32500397 http://dx.doi.org/10.1007/s10549-020-05701-7

Ejemplares similares

Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study
por: Buono, Giuseppe, et al.
Publicado: (2017)

Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy
por: Arpino, Grazia, et al.
Publicado: (2015)

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
por: Schettini, Francesco, et al.
Publicado: (2018)

Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients
por: Crispo, Anna, et al.
Publicado: (2023)

Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series
por: Schettini, Francesco, et al.
Publicado: (2020)

Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis
por: De Angelis, Carmine, et al.
Publicado: (2017)

Tumor characteristics and prognosis in familial breast cancer
por: Arpino, G., et al.
Publicado: (2016)

Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study
por: Di Maio, Massimo, et al.
Publicado: (2023)

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
por: De Angelis, C., et al.
Publicado: (2021)

Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis
por: Gargiulo, Piera, et al.
Publicado: (2016)

Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series
por: Crispo, Anna, et al.
Publicado: (2013)

Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study
por: Arpino, Grazia, et al.
Publicado: (2015)

It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature
por: Pensabene, Matilde, et al.
Publicado: (2018)

Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach
por: Fabi, Alessandra, et al.
Publicado: (2022)

Corrigendum to ‘Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)’: [ESMO Open Volume 6, Issue 2, April 2021, 100054]
por: De Angelis, C., et al.
Publicado: (2021)

Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer
por: Buonaiuto, Roberto, et al.
Publicado: (2022)

Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests
por: Saponaro, Mariarosaria, et al.
Publicado: (2022)

Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial
por: Capasso, Immacolata, et al.
Publicado: (2013)

Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
por: Schettini, Francesco, et al.
Publicado: (2021)

Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype
por: Capasso, Immacolata, et al.
Publicado: (2014)

Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications
por: De Placido, S, et al.
Publicado: (2017)

Prevalence of Sarcopenia in Women with Breast Cancer
por: Morlino, Delia, et al.
Publicado: (2022)

Quality of Life in Women Diagnosed with Breast Cancer after a 12-Month Treatment of Lifestyle Modifications
por: Montagnese, Concetta, et al.
Publicado: (2020)

Glucocorticoid Receptor and Ovarian Cancer: From Biology to Therapeutic Intervention
por: Buonaiuto, Roberto, et al.
Publicado: (2023)

Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study
por: De Placido, Pietro, et al.
Publicado: (2022)

Strategies to evaluate outcomes in long-COVID-19 and post-COVID survivors
por: Crispo, Anna, et al.
Publicado: (2021)

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
por: Schettini, F., et al.
Publicado: (2021)

Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis
por: Isgrò, Maria Antonietta, et al.
Publicado: (2021)

CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).
por: De Placido, S., et al.
Publicado: (1995)

Long Non-Coding RNA HOTAIR in Breast Cancer Therapy
por: Cantile, Monica, et al.
Publicado: (2020)

Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial
por: Porciello, Giuseppe, et al.
Publicado: (2020)

Correction: Mediterranean diet and quality of life in women treated for breast cancer: A baseline analysis of DEDiCa multicentre trial
por: Porciello, Giuseppe, et al.
Publicado: (2021)

Insights into the Friedel–Crafts Benzoylation of N-Methylpyrrole inside the Confined Space of the Self-Assembled Resorcinarene Capsule
por: Iuliano, Veronica, et al.
Publicado: (2023)

The role of taxanes in triple-negative breast cancer: literature review
por: Mustacchi, Giorgio, et al.
Publicado: (2015)

Rare tumours of the breast
por: Esposito, Emanuela, et al.
Publicado: (2019)

Mortality Trend for Tumor Correlated Immune System in Hyperendemic Area of HCV Infection in Southern Italy: Joinpoint Analysis
por: Montella, Maurizio, et al.
Publicado: (2013)

Calix[6]arene-based atropoisomeric pseudo[2]rotaxanes
por: Gaeta, Carmine, et al.
Publicado: (2018)

A meta-analytic review of the relationship of cancer coping self-efficacy with distress and quality of life
por: Chirico, Andrea, et al.
Publicado: (2017)

Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie
por: De Angelis, Carmine, et al.
Publicado: (2021)

Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice
por: Buono, Giuseppe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ecvn5j001l41ekmue665sd9pl0